Odevixibat

奥德昔巴特

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameOdevixibat
Drug Alias NameOdevixibat sesquihydrateBylvayODEVIXIBAT1蓓尔唯AR-H064974 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIleal bile acid transporter inhibitors
TargetsIleal bile acid transporter
Therapy Area/IndicationsProgressive familial intrahepatic cholestasisPruritusLiver Diseases +[6] 
Global Approved IndicationsProgressive familial intrahepatic cholestasisPruritus
Approved Indications in ChinaProgressive familial intrahepatic cholestasisPruritus
Original Approved Country/TerritoryEU
Original Approved Date2021/07/16
Country/TerritoryBelgiumCanadaUnited States +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAlbireo Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesMedison PharmaIpsenAlbireo Inc +[10] 
Inactive CompaniesIpsen (Tianjin) Pharmaceutical Trade Co Ltd
Active IndicationsProgressive familial intrahepatic cholestasisPruritusAlagille Syndrome +[4] 
Inactive IndicationsLiver DiseasesLiver Cirrhosis, Biliary

Other Information

ATC CodeA05AX
Related LinksDrugBankKEGG